About This Calculator

The Amjevita (adalimumab-atto) Dosing Calculator is an educational resource designed for healthcare professionals to quickly determine recommended dosing schedules based on patient population, approved indication, and other relevant clinical factors. This guide provides supplementary information on how the tool functions, its outputs, and key dosing considerations based on the official prescribing information.

Outputs

Upon entering the required patient parameters, the calculator provides the following information:

• Recommended Dose: The specific milligram (mg) strength and administration timing (e.g., 160 mg on Day 1).
• Dosing Schedule: The frequency of administration, such as “every other week” or “every week”.
• Dosing Phase: Clarifies whether the output is for the induction (initial loading dose) or maintenance phase of treatment.
• Patient Grouping: For pediatric indications, it specifies the relevant weight-based cohort (e.g., ≥30 kg).
• Clinical Notes: Important context, such as considerations for patients not receiving concomitant methotrexate, is provided where applicable.

How to Use

To use the calculator, follow these steps:

1. Select Patient Population: Choose between “Adult” and “Pediatric”. This selection dynamically updates the available indications.
2. Select Indication: From the dropdown menu, choose the relevant FDA-approved indication for Amjevita.
3. Enter Patient Weight (Pediatric only): If “Pediatric” is selected, the patient’s weight must be entered. You can toggle between kilograms (kg) and pounds (lbs).
4. Select Dosing Phase: For indications with a loading dose, specify whether you are calculating for the “Induction” or “Maintenance” phase.
5. Specify Concomitant Therapy: For certain indications like Rheumatoid Arthritis, specify if the patient is taking concomitant methotrexate.

Dosing Overview

Amjevita dosing regimens are specific to the indication and patient population. Generally, many inflammatory conditions involve an initial higher-dose induction period followed by a lower, regular maintenance dose.

• Adult Dosing: For many adult indications (e.g., RA, PsA, AS), the standard maintenance dose is 40 mg every other week. Indications like Crohn’s Disease, Ulcerative Colitis, and Hidradenitis Suppurativa require a 160 mg induction dose at Week 0, followed by 80 mg at Week 2, before starting maintenance therapy.
• Pediatric Dosing: Dosing in pediatric patients is almost always weight-based. The calculator stratifies dosing based on established weight categories (e.g., 15 kg to <30 kg) as defined in the prescribing information.

Switching

When switching a patient from another TNF blocker to Amjevita, healthcare providers should exercise clinical judgment. The first dose of Amjevita should typically be administered on the day the next dose of the previous therapy was scheduled. Always consult the full prescribing information and relevant clinical guidelines when making treatment transitions.

Missed Dose

If a patient misses a dose of Amjevita, they should be instructed to administer the injection as soon as they remember. They should then take their next dose at the regularly scheduled time. This will re-establish their treatment schedule. Patients should be advised not to take two doses at the same time to make up for a missed dose.

Safety Alerts

Amjevita, an adalimumab biosimilar, is a TNF blocker that affects the immune system. It carries a Boxed Warning regarding the increased risk of serious infections and malignancy.

• Serious Infections: Patients treated with adalimumab products are at increased risk for developing serious infections that may lead to hospitalization or death. These include tuberculosis (TB), invasive fungal, bacterial, viral, and other opportunistic infections.
• Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including adalimumab products.

Frequently Asked Questions (FAQ)

Why is weight required for pediatric patients but not adults?

The approved dosing for pediatric indications is weight-based to ensure appropriate exposure and efficacy in a growing population. Adult dosing is standardized for most indications, regardless of weight.

What is the difference between the induction and maintenance phases?

The induction phase involves a higher initial dose (a “loading dose”) to quickly achieve therapeutic levels of the medication. The maintenance phase is the subsequent, ongoing dosing schedule designed to maintain those levels over time.

Does this calculator account for concomitant methotrexate (MTX) use?

Yes. For indications where MTX use affects the recommended dosing, such as Rheumatoid Arthritis (RA), the calculator provides an option to specify this, adjusting the output according to the prescribing information.

What does “EOW” in the results stand for?

“EOW” is a common medical abbreviation for “Every Other Week.”

Why does the Crohn’s disease regimen start with 160 mg?

The 160 mg loading dose at Week 0, followed by 80 mg at Week 2, is the FDA-approved induction regimen to rapidly control inflammation and induce a clinical response in patients with moderately to severely active Crohn’s disease.

The calculator gave an error for my pediatric patient’s weight. Why?

Amjevita has specific weight cutoffs for its pediatric indications. If a patient’s weight is below the approved minimum for a selected condition (e.g., less than 17 kg for pediatric Crohn’s Disease), the calculator will indicate that it is not indicated, as per the prescribing information.

Can the 160 mg dose be given as a single injection?

No, the 160 mg dose must be administered as either four 40 mg injections or two 80 mg injections on the same day. The calculator’s notes often clarify this administration detail.

References

1. Amjevita (adalimumab-atto) Prescribing Information. U.S. Food and Drug Administration.
2. Amjevita Official Website. Amgen Inc.
3. American College of Rheumatology (ACR) Guideline for the Treatment of Rheumatoid Arthritis.
4. Biologic Therapy for IBD. Crohn’s & Colitis Foundation.